No connection

Search Results

GDTC vs SINT

GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%
SINT
Sintx Technologies, Inc.
BEARISH
Price
$2.69
Market Cap
$11.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
GDTC
--
SINT
--
Forward P/E
GDTC
-6.67
SINT
-1.53
P/B Ratio
GDTC
2.31
SINT
3.64
P/S Ratio
GDTC
13.74
SINT
10.89
EV/EBITDA
GDTC
-2.73
SINT
-1.0

Profitability

Gross Margin
GDTC
89.57%
SINT
45.28%
Operating Margin
GDTC
-535.25%
SINT
-787.59%
Profit Margin
GDTC
0.0%
SINT
0.0%
ROE
GDTC
-50.28%
SINT
-303.8%
ROA
GDTC
-29.31%
SINT
-69.8%

Growth

Revenue Growth
GDTC
46.9%
SINT
-46.5%
Earnings Growth
GDTC
--
SINT
--

Financial Health

Debt/Equity
GDTC
0.07
SINT
1.11
Current Ratio
GDTC
5.17
SINT
1.51
Quick Ratio
GDTC
3.14
SINT
1.16

Dividends

Dividend Yield
GDTC
--
SINT
--
Payout Ratio
GDTC
0.0%
SINT
0.0%

AI Verdict

GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage
SINT BEARISH

SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.

Strengths
Positive Gross Margin (45.28%) suggesting some product-level viability
Current Ratio of 1.51 provides a minimal short-term liquidity buffer
Quick Ratio of 1.16 indicates ability to cover immediate liabilities
Risks
Severe revenue contraction (-46.50% YoY)
Extreme operational inefficiency (Operating Margin -787.59%)
Massive equity erosion (ROE -303.80%)

Compare Another Pair

GDTC vs SINT: Head-to-Head Comparison

This page compares CytoMed Therapeutics Limited (GDTC) and Sintx Technologies, Inc. (SINT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile